Consultants and Advisors

Henry F. VanBrocklin received his Ph.D. in Radiopharmaceutical Chemistry from Washington University St. Louis under the mentorship of Prof. Michael Welch. He furthered the development of positron‐labeled estrogens, progestins and androgens for tumor imaging. As a US Department of Energy Alexander Hollander Distinguished Postdoctoral Fellowship he continued his research on positron labeled steroids and fatty acids in the laboratory of Prof. John Katzenellenbogen at the University of Illinois. In 1992 Dr. VanBrocklin moved to Lawrence Berkeley National Laboratory where he was a Staff Scientist and Radiopharmaceutical Chemistry Group Leader in the Department of Functional Imaging. He is currently Professor of Radiology at the University of California San Francisco (UCSF) and Director of Radiopharmaceutical Research in the Center for Functional and Molecular Imaging. He is also President of the Molecular Imaging Center of Excellence for the Society of Nuclear Medicine. He has built a successful radiotracer development program with many active collaborations. His work in the field spans many disciplines from short‐lived radioisotope production to the creation of fluorine 18 and carbon‐11 labeling chemistry strategies for new radiotracer preparation and application. His current research interests include development of radiopharmaceutical probes for PET and SPECT blood flow measurement and imaging agents targeting cancer cell surface markers. He has been very active within the SNM Leadership as the President of the Radiopharmaceutical Sciences Council and recently as Chair the Committee on Councils. He has also contributed to the SNM's Molecular Imaging strategic plan.[CLOSE BIO]

Dr. Benny is Assistant Professor in the Analytical Division of the Department of Chemistry at Washington State University. Dr. Benny has particular expertise in radiopharmaceutical chemistry and is interested in the development and characterization of radioactive metal complexes for diagnosis and treatment of biological diseases. Dr. Benny is responsible for radiolabeling techniques associated with CTT-54 and creating the final radiopharmaceutical for subsequent development work. Dr. Benny received a BS in Chemistry and in Mathematics from Missouri Baptist College and a PhD in inorganic chemistry from University of Missouri.[CLOSE BIO]

Dr. Bryan is Assistant Professor in the Veterinary Medicine Department at Washington State University. Dr. Bryan works in collaboration with Dr. Berkman at WSU and is responsible for supervising all animal studies and coordinating and analyzing preclinical imaging studies. Dr. Bryan works in collaboration with both Cliff and Paul to image tumor bearing animals injected with labeled CTT-54. Dr. Bryan holds a PhD from the University of Missouri and a DVM from the University of California, Davis. [CLOSE BIO]

Mr. Kitteridge has pharmaceutical and device regulatory expertise in early stage development projects. Mr. Ketteridge has extensive experience in quality assurance and document control and in writing/reviewing INDs, NDAs, PMAs, clinical protocols for FDA/IRB or foreign equivalents submission. He has over a decade of industrial experience including positions at various biotechnology companies where his responsibilities included managing regulatory, safety and document control functions. Mr. Ketteridge also has served at the Center for Drug Evaluation and Research at the Food and Drug Administration. Mr. Ketteridge is helping CTT with the regulatory issues associated with the IND and subsequent clinical trials for CTT-54. Mr. Ketteridge holds a B.S. in Pharmacy from the University of Washington.[CLOSE BIO]